WHAT IS CLAIMED IS:

1. A liposomal formulation comprising:

a) a liposome having an active agent encapsulated therein; and

b) an empty liposome.

2. The liposomal formulation of claim **1**, wherein the ratio of liposomes containing said active agent to said empty liposomes is from about 1:0.5 to 1:1000.

3. The liposomal formulation of claim **2**, wherein the ratio of liposomes containing said active agent to said empty liposomes is from about 1:1 to 1:100.

4. The liposomal formulation of claim **3**, wherein the ratio of liposomes containing said active agent to said empty liposomes is from about 1:2 to 1:10.

5. The liposomal formulation of claim **4**, wherein the ratio of liposomes containing said active agent to said empty liposomes is from about 1:3 to 1:5.

6. The liposomal formulation of claim **1**, wherein said active agent is an antineoplastic drug.

7. The liposomal formulation of claim **6**, wherein said antineoplastic drug is a camptothecin.

8. The liposomal formulation of claim **7**, wherein said camptothecin is a member selected from the group consisting of irinotecan, topotecan, 9-amino camptothecin, 10,11-methylenedioxy camptothecin, 9-nitro camptothecin, TAS 103, 7-(4-methyl-piperazino-methylene)-10, 11-ethylenedioxy-20(S)-camptothecin and 7-(2-N-isopropylamino)ethyl)-20(S)-camptothecin.

9. The liposomal formulation of claim **8**, wherein said camptothecin is topotecan.

10. The liposomal formulation of claim **9**, wherein said antineoplastic drug is a vinca alkaloid.

11. The liposomal formulation of claim **10**, wherein said vinca alkaloid is a member selected from the group consisting of vincristine, vinblastine, vinorelbine and vindesine.

12. The liposomal formulation of claim **11**,wherein said vinca alkaloid is vincristine.

13. The liposomal formulation of claim **11**, wherein said vinca alkaloid is vinorelbine.

14. The liposomal formulation of claim **1**, wherein the ratio of said active agent to lipid is about 0.005-1:1 (w/w).

15. The liposomal formulation of claim **14**, wherein the ratio of said active agent to lipid is about 0.05-0.9:1 (w/w).

16. The liposomal formulation of claim **15**, wherein the ratio of said active agent to lipid is about 0.1-0.5:1 (w/w).

17. The liposomal formulation of claim **1**, wherein said active agent comprises free active agent and precipitated active agent.

18. The liposomal formulation of claim **17**, wherein at least 50% of said active agent is precipitated active agent.

19. The liposomal formulation of claim **1**, wherein said liposomes containing said active agent comprise sphingomyelin.

20. The liposomal formulation of claim **19**, further comprising cholesterol.

21. The liposomal formulation of claim **20**, wherein the sphingomyelin and cholesterol are present at a molar ratio from 75/25 mol%/mol% sphingomyelin/cholesterol to 30/50 mol%/mol% sphingomyelin/cholesterol.